Early neurological worsening in patients with Wilson's disease


      • Early neurological worsening is observed in almost 11% of WD patients.
      • It is limited to cases with neurological signs at the beginning of WD treatment.
      • It is usually reversible in most of the cases (66%).
      • It may be associated with several clinical, imaging and pharmacological factors.
      • The type of anti-copper therapy seems to have no clear impact.



      Early neurological worsening during treatment initiation for Wilson's disease (WD) is an unresolved problem. Our aim was to establish the frequency and outcome of early neurological worsening in patients with WD.


      We analyzed 143 symptomatic patients diagnosed with WD between 2005 and 2009. Early neurological deterioration was based on worsening on the Unified Wilson's Disease Score Scale, scored at baseline through 6 months or occurrence of new neurological symptoms. Reversibility of worsening was followed up to 24 months.


      Early neurological worsening was observed in 11.1% (16/143) and involved only patients with neurological signs at diagnosis. Mean time to worsening from treatment initiation was 2.3 ± 1.9 months. Neurological deterioration was completely reversible in 53% (8/15) and partially in 13% (2/15) of patients over 9.2 ± 5.2 months. Patients who experienced early deterioration had significantly more severe baseline neurological deficit, higher prevalence of thalamic (66% vs 29%) and brain stem (73% vs 33%) lesions seen on baseline magnetic resonance imaging, and more often used concomitant dopamine receptor antagonists (46% vs 5%). Disease duration, treatment type (d-penicillamine or zinc sulfate), type of neurological manifestations, initial copper metabolism results, and liver function parameters did not differ between evaluated groups.


      Neurological worsening at the beginning of anti-copper therapy may occur in over 10% of WD patients. Special attention should be paid to those with severe initial neurological manifestations, advanced brain injury and using dopamine receptor antagonists. Type of anti-copper therapy did not show clear association with early neurological worsening.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Roberts E.
        • Schilsky M.
        Diagnosis and treatment of Wilson's disease an update.
        Hepatology. 2008; 47: 2089-2111
        • European Association For The Study of The Liver Disease
        EASL clinical practice guidelines: Wilson's disease.
        J. Hepatol. 2012; 56: 671-685
        • Brewer G.J.
        Risks of copper and iron toxicity during aging in humans.
        Chem. Res. Toxicol. 2010; 23: 319-326
        • Cummings J.N.
        The effect of BAL in hepatolenticular degeneration.
        Brain. 1951; 74: 10-22
        • Walshe J.M.
        Wilson's disease. New oral therapy.
        Lancet. 1956; : 25-26
        • Hoogenrad T.U.
        • Van Hattum J.
        • Van den Hamer C.J.
        Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients.
        J. Neurol. Sci. 1987; 77: 137-146
        • Hoogenraad T.U.
        • Koevoet R.
        • de Ruyter Korver E.G.
        Oral zinc sulphate as long term treatment in Wilson's disease (hepatolenticular degeneration).
        Eur. Neurol. 1979; 18: 205-211
        • Brewer G.
        Zinc and tetrathiomolybdate for treatment of Wilson's disease and the potential efficacy of anticopper therapy in wide variety of diseases.
        Metallomics. 2009; 1: 199-206
        • Brewer G.
        Penicillamine should not be used as initial therapy in Wilson's disease.
        Mov. Disord. 1999; 14: 551-554
        • Weiss K.H.
        • Gothardt D.N.
        • Klemm D.
        • et al.
        Zinc monotherapy is not as effective as chelating agents in treatment of Wilson's disease.
        Gastroenterology. 2011; 140: 1189-1198
        • Wiggelinkhuizen M.
        • Tilanus M.E.C.
        • Bollen C.W.
        • Houwen H.J.
        Systemic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson's disease.
        Aliment. Pharmacol. Ther. 2009; 29: 947-958
        • Brewer G.J.
        • Terry C.A.
        • Aisen A.M.
        • et al.
        Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy.
        Arch. Neurol. 1987; 44: 490-493
        • Kim B.
        • Chung S.J.
        • Shin H.W.
        Trientine-induced neurological deterioration in patient with Wilson's disease.
        J. Clin. Neurosci. 2013; 20: 1398-1401
        • Medici V.
        • Trevisan C.P.
        • D'Inca R.
        • Barollo M.
        • Zancan L.
        Diagnosis and management of Wilson's disease: results of a single center experience.
        J. Clin. Gastroenterol. 2006; 40: 936-941
        • Brewer G.
        • Dick D.R.
        • Johnson V.D.
        • Brunberg J.
        Treatment of Wilson's disease with zinc: XV long term follow-up studies.
        J. Lab. Clin. Med. 1998; 132: 264-278
        • Brewer G.J.
        Neurologically presenting Wilson's disease.
        CNS Drugs. 2005; 19: 185-192
        • Chen D.B.
        • Feng L.
        • Lin X.P.
        • et al.
        Penicillamine increases free copper and enhances oxidative stress in the brain of toxic milk mice.
        PLoS One. 2012; 7: e37709
        • Czlonkowska A.
        • Gajda J.
        • Rodo M.
        Effects of long-term treatment in Wilson's disease with d-penicillamine and zinc sulphate.
        J. Neurol. 1996; 243: 269-273
        • Czlonkowska A.
        • Litwin T.
        • Karlinski M.
        • Dziezyc K.
        • Chabik G.
        • Czerska M.
        d-Penicillamine versus zinc sulfate as first-line therapy for Wilson's disease.
        Eur. J. Neurol. 2014; 21: 599-606
        • Czlonkowska A.
        • Tarnacka B.
        • Litwin T.
        • Gajda J.
        • Rodo M.
        Wilson's disease cause of mortality in 164 patients during 1992–2003 observation period.
        J. Neurol. 2005; 252: 698-703
        • Maselbas W.
        • Chabik G.
        • Czlonkowska A.
        Persistence with treatment in patients with Wilson disease.
        Neurol. Neurochir. Pol. 2010; 44: 260-263
        • Fereci P.
        • Caca K.
        • Loudianos G.
        • et al.
        Diagnosis and phenotypic classification of Wilson's diseases.
        Liver Int. 2003; 23: 139-142
        • Czlonkowska A.
        • Tarnacka B.
        • Moller J.C.
        • et al.
        Unified Wilson's Diseases Rating Scale — proposal for the neurological scoring of Wilson's disease patients.
        Neurol. Neurochir. Pol. 2007; 41: 1-12
        • Leinweber B.
        • Moller J.C.
        • Scheraq A.
        • et al.
        Evaluation of the Unified Wilson's Disease Rating Scale (UWDRS) in German patients with treated Wilson's disease.
        Mov. Disord. 2008; 23: 54-62
        • Litwin T.
        • Gromadzka G.
        • Czlonkowska A.
        Gender differences in Wilson's disease.
        J. Neurol. Sci. 2012; 312: 31-35
        • Litwin T.
        • Gromadzka G.
        • Czlonkowska A.
        • Gołębiowski M.
        • Poniatowska R.
        The effect of gender on brain MRI pathology in Wilson's disease.
        Metab. Brain Dis. 2013; 28: 69-75
        • Litwin T.
        • Gromadzka G.
        • Czlonkowska A.
        Neurological presentation of Wilson's disease in a patient after liver transplantation.
        Mov. Disord. 2008; 23: 743-745
        • Stuerenburg H.J.
        CSF copper concentrations, blood–brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease.
        J. Neural Transm. 2000; 107: 321-329
        • Huang C.C.
        • Chu N.S.
        Acute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in Wilson's disease.
        Eur. Neurol. 1998; 1: 32-37
        • Kalita J.
        • Kumar V.
        • Chandra S.
        • Kumar B.
        • Misra U.K.
        Worsening of Wilson disease following penicillamine therapy.
        Eur. Neurol. 2014; 71: 126-131
        • Tarnacka B.
        • Szeszkowski W.
        • Gołębiowski M.
        • Członkowska A.
        Metabolic changes in 37 newly diagnosed Wilson's disease patients assessed by magnetic resonance spectroscopy.
        Parkinsonism Relat. Disord. 2009; 15: 582-586
        • Prayer L.
        • Wimberger J.
        • Kramer J.
        • Grimm G.
        • Oder W.
        • Imhof H.
        Cranial MRI in Wilson's disease.
        Neuroradiology. 1990; 32: 211-214
        • Brewer G.
        • Askari F.
        • Lorincz M.T.
        • Carlson M.
        • Schilsky M.
        • Kluin K.J.
        • et al.
        Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in double-blind study of treatment of the neurologic presentation of Wilson disease.
        Arch. Neurol. 2006; 63: 521-527
        • Litwin T.
        • Chabik G.
        • Czlonkowska A.
        Acute focal dystonia induced by tricyclic antidepressant in patient with Wilson diseases: a case report.
        Neurol. Neurochir. Pol. 2013; 47: 502-506
        • Litwin T.
        • Gromadzka G.
        • Samochowiec J.
        • Grzywacz A.
        • Czlonkowski A.
        • Czlonkowska A.
        Association of dopamine receptor gene polymorphisms with the clinical course of Wilson disease.
        JIMD Rep. 2013; 8: 73-80
        • Oder W.
        • Brucke T.
        • Kolleger H.
        • Spatt J.
        • Asenbaum S.
        • Deedke L.
        Dopamine receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal I–Iodobenzamide binding.
        J. Neural Transm. 1996; 103: 1096-1103
        • Schlaug G.
        • Hefter H.
        • Nebeling B.
        • Engelbrecht V.
        • Weiss P.
        • Stocklin G.
        • et al.
        Dopamine D2 receptor binding and cerebral glucose metabolism recover after d-penicillamine-therapy in Wilson's disease.
        J. Neurol. 1994; 241: 577-584
        • Madhusoodanan S.
        • Alexeenko L.
        • Sanders R.
        • Brenner R.
        Extrapyramidal symptoms associated with antidepressants — a review of the literature and analysis of spontaneous reports.
        Ann. Clin. Psychiatry. 2010; 22: 148-156